Catabasis Pharmaceuticals Receives $39,600,000 Series A Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=185dbbe5-4be9-40ad-9eb9-d66080961dcc&Preview=1
Date
4/21/2010
Company Name
Catabasis Pharmaceuticals
Mailing Address
161 1st St. Cambridge, MA 02142
Company Description
At Catabasis we are dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We have assembled a team of highly motivated and experienced scientists who are committed to improving the lives of patients.
Website
http://www.catabasispharma.com/index.html
Transaction Type
Venture Equity
Transaction Amount
$39,600,000
Transaction Round
Series A
Proceeds Purposes
Proceeds from the financing will be used to advance Catabasis’ lead program targeting type 2 diabetes, and to further the development of the company’s proprietary platform technology in additional inflammatory and metabolic diseases.
M&A Terms
Venture Investor
SV Life Sciences
Venture Investor
Clarus Ventures
Venture Investor
MedImmune Ventures
Venture Investor
Advanced Technology Ventures